MEDPRIN REGENERATIVE MEDICAL TECHNOLOGIES CO., LTD. Medprin Regenerative Medical Technologies Co., Ltd. Stock
Equities
301033
CNE100004NB8
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.83 CNY | +2.47% |
|
+24.04% | -20.00% |
| Sales 2024 * | 288M 39.75M | Sales 2025 * | 377M 52M | Capitalization | 2.3B 318M |
|---|---|---|---|---|---|
| Net income 2024 * | 67M 9.25M | Net income 2025 * | 105M 14.49M | EV / Sales 2024 * | 7.99 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.11 x |
| P/E ratio 2024 * |
33.8
x | P/E ratio 2025 * |
21.9
x | Employees | 279 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.47% | ||
| 1 week | +24.04% | ||
| Current month | +3.05% | ||
| 1 month | +6.03% | ||
| 3 months | -5.17% | ||
| 6 months | -1.97% | ||
| Current year | -20.00% |
1 week
30.88
36.19
1 month
25.6936.19
Current year
22.3744.45
1 year
22.3753.00
3 years
22.3785.57
5 years
22.3785.57
10 years
22.3785.57
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Yu Yuan
CEO | Chief Executive Officer | 44 | 08-08-31 |
Ya Hong Luo
DFI | Director of Finance/CFO | 56 | 17-01-31 |
Kun Xue Deng
CTO | Chief Tech/Sci/R&D Officer | - | 11-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xin Lu
BRD | Director/Board Member | 61 | 18-10-31 |
Yu Yu Yuan
CEO | Chief Executive Officer | 44 | 08-08-31 |
Ya Hong Luo
DFI | Director of Finance/CFO | 56 | 17-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 34.83 | +2.47% | 1,883,436 |
| 24-04-25 | 33.99 | +1.10% | 1,699,004 |
| 24-04-24 | 33.62 | -0.53% | 1,274,531 |
| 24-04-23 | 33.8 | 0.00% | 2,015,851 |
| 24-04-22 | 33.8 | +0.30% | 2,657,711 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Medprin Regenerative Medical Technologies Co Ltd is a China-based company principally engaged in the research and development, production and sales of high-performance implantable medical devices. The Company's implanted medical device products include artificial dura mater (spine) patch, cranio-maxillofacial repair products and absorbable hemostatic yarns. 3D printing equipment includes biological 3D printers, resin 3D printers and other related supporting components. Technical services include general technical services and scientific research services. The Company distributes its products both in the domestic market and to overseas markets.
Calendar
2024-05-10
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
34.83
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 310M | |
| +12.07% | 128B | |
| -9.04% | 10.51B | |
| +0.91% | 8.71B | |
| +16.72% | 7B | |
| +25.15% | 5.02B | |
| +7.17% | 3.39B | |
| -1.36% | 3.02B | |
| -8.73% | 2.07B | |
| -10.15% | 2.06B |
- Stock Market
- Equities
- 301033 Stock
